View all newsletters
Receive our newsletter - data, insights and analysis delivered to you
  1. News
September 22, 2022

C₂N Diagnostics and Grupo Fleury partner for Alzheimer’s blood test

The collaboration will provide patients with access to C₂N Diagnostics’ suite of new, Alzheimer-detecting plasma biomarkers.

C₂N Diagnostics and healthcare company Grupo Fleury have collaborated to bring blood-based tests for early-stage Alzheimer’s diagnosis to Brazil.

The collaboration is aimed at introducing an advanced set of plasma biomarkers that are used to identify changes that indicate the presence of Alzheimer’s disease pathology in people experiencing memory difficulties.

Through this partnership, patients will get access to C₂N Diagnostics’ suite of new blood-based biomarkers, which can detect Alzheimer’s disease at an early stage and without using invasive or radioactive methods.

According to data from the Brazilian Ministry of Health data, there are nearly 1.2 million Alzheimer’s disease cases in Brazil.

Across the world, there are 35.6 million people living with the condition.

C₂N Diagnostics co-founder and scientific advisor Dr Ilana Fogelman said: “Patients deserve early and accurate diagnosis, which represent the first steps toward proper treatment and optimal care planning.

“With Grupo Fleury’s leadership, we are very much looking forward to bringing our Precivity-related blood testing products to patients in Brazil in a convenient and widely accessible manner.”

Last month, C₂N Diagnostics and Healius collaborated to bring the PrecivityAD blood test and related brain health biomarkers for dementia care to Australia.

The PrecivityAD test helps to determine the likelihood of amyloid plaques in an individual’s brain.

In May, C₂N Diagnostics also took part in the Global Health Care Preparedness Project with the Davos Alzheimer’s Collaborative (DAC).

In this initiative, DAC announced the launch of seven pilot sites, located in the US, Scotland, Jamaica, Japan, Mexico and Brazil, that will use simple digital cognitive assessment tools, including C₂N Diagnostics’ PrecivityAD blood test, to increase the diagnosis of Alzheimer’s.

Related Companies

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. The top stories of the day delivered to you every weekday. A weekly roundup of the latest news and analysis, sent every Friday. The medical device industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU

Thank you for subscribing to Medical Device Network